Advertisement

Topics

"Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration" Drugs and Medication Database

20:21 EST 20th February 2019 | BioPortfolio

Here are the most relevant "Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration" Drugs and Medications that we have found in our database.

More Information about "Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration" on BioPortfolio

We have published hundreds of Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration news stories on BioPortfolio along with dozens of Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration Clinical Trials and PubMed Articles about Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration Companies in our database. You can also find out about relevant Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration Drugs and Medications on this site too.

Showing "Long term Results After Intravitreal Bevacizumab Treatment Neovascular" Drugs and Medications, all 17

Relevant

Mvasi [amgen inc]

These highlights do not include all the information needed to use MVASI safely and effectively. See full prescribing information for MVASI .     MVASI (bevacizumab-awwb ) Solution for intravenous infusion Initial U.S. Approval: 2017 MVASI (bevacizumab-

Macugen [bausch & lomb incorporated]

These highlights do not include all the information needed to use MACUGEN safely and effectively. See full prescribing information for MACUGEN. MACUGEN(pegaptanib sodium injection)Intravitreal InjectionInitial U.S. Approval: 2004

Probably Relevant

Eylea [regeneron pharmaceuticals, inc.]

These highlights do not include all the information needed to use EYLEA safely and effectively. See full prescribing information for EYLEA. EYLEA (aflibercept) Injection, for Intravitreal InjectionInitial U.S. Approval: 2011

Lucentis [genentech, inc.]

These highlights do not include all the information needed to use LUCENTIS safely and effectively. See full prescribing information for LUCENTIS. LUCENTIS (ranibizumab injection) for intravitreal injection Initial U.S. Approval: 2006

Jetrea [thrombogenics inc.]

These highlights do not include all the information needed to use JETREA safely and effectively. See full prescribing information for JETREA JETREA (ocriplasmin) injection, for intravitreal injectionInitial U.S. Approval: 2012

Possibly Relevant

Yutiq [eyepoint pharmaceuticals us, inc]

These highlights do not include all the information needed to use YUTIQ safely and effectively. See full prescribing information for YUTIQ.YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injectionInitial U.S. Approval: 1963

Iluvien [alimera sciences, inc.]

These highlights do not include all the information needed to use ILUVIEN® safely and effectively. See full prescribing information for ILUVIEN. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg For Intravitreal Injection Initial U.S. Appro

Tecentriq [genentech, inc.]

These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. TECENTRIQ (atezolizumab) injection, for intravenous useInitial U.S. Approval: 2016

Ozurdex [allergan, inc.]

These highlights do not include all the information needed to use OZURDEX® safely and effectively. See full prescribing information for OZURDEX . OZURDEX (dexamethasone intravitreal implant) For Intravitreal Injection Initial U.S. Approval: 1958

Visudyne [qlt ophthalmics, inc.]

VISUDYNE (VERTEPORFIN FOR INJECTION)

Retisert [bausch & lomb incorporated]

These highlights do not include all the information needed to use RETISERT safely and effectively. See full prescribing information for RETISERT. RETISERT (fluocinolone acetonide intravitreal implant) 0.59 mg for intravitreal use Initial U.S. Approval: 19

Avastin [genentech, inc.]

These highlights do not include all the information needed to use AVASTIN safely and effectively. See full prescribing information for AVASTIN. AVASTIN (bevacizumab) injection, for intravenous useInitial U.S. Approval: 2004

Firvanq [cutispharma, inc.]

These highlights do not include all the information needed to use FIRVANQ™ safely and effectively. See full prescribing information for FIRVANQ . FIRVANQ (vancomycin hydrochloride) , for oral solution Initial U.S. Approval: 196 4

Cyramza [eli lilly and company]

These highlights do not include all the information needed to use CYRAMZA safely and effectively. See full prescribing information for CYRAMZA.CYRAMZA (ramucirumab) injection, for intravenous useInitial U.S. Approval: 2014

Travatan z [physicians total care, inc.]

These highlights do not include all the information needed to use TRAVATAN Z (travoprost ophthalmic solution) 0.004% safely and effectively. See full prescribing information for TRAVATAN Z . TRAVATAN Z (travoprost ophthalmic solution) 0.004% Initial U.S.

Travatan z [alcon laboratories, inc]

These highlights do not include all the information needed to use TRAVATAN Z safely and effectively. See full prescribing information for TRAVATAN Z.TRAVATAN Z (travoprost ophthalmic solution) 0.004% for topical ophthalmic useInitial U.S. Approval: 2001

Visudyne [valeant pharmaceuticals north america llc]

These highlights do not include all the information needed to use VISUDYNE® safely and effectively. See full prescribing information for VISUDYNE®.VISUDYNE® (verteporfin for injection), for intravenous useInitial U.S. Approval: 2000



Advertisement
Quick Search
Advertisement
Advertisement